Abstract Details

Title Subcutaneous Interferon ?-1a in Children and Adolescents with Multiple Sclerosis: Regional Differences in Outcomes and Treatment Patterns in the International REPLAY Study

Topic MS and Related Diseases

Presentation(s) S41 - (-)

Poster/Presentation
Number 007

Objective

Background The REPLAY study showed adult doses of subcutaneous (sc) interferon (IFN) ?-1a, 44 and 22 [micro]g three times weekly, were well tolerated and associated with reduced relapse rates in a pediatric MS population.

Design/Methods Using data obtained retrospectively from medical records, REPLAY investigated the safety and efficacy of sc IFN ?-1a treatment in pediatric patients with MS.

Results The study included 307 patients: USA n=139 (45.3%); other countries (OC) n=168 (54.7%). The mean (SD) age at MS diagnosis was 13.2 (3.2) years. Compared with OC patients, US patients had higher mean body mass index (BMI; 26 vs. 21 kg/m2), shorter median time from first demyelinating event to first disease-modifying drug (DMD) (0.7 vs. 1.1 years), and were more likely to have received ?1 other DMD before sc IFN ?-1a (33.8% vs. 13.7%). An initial sc IFN ?-1a dose of 44 [micro]g was more common in the USA (88.9%) than OC (24.3%). US patients also had a shorter median treatment duration (1.07 vs. 1.73 years) and were more likely to switch to another DMD (28.8% vs. 13.1%). 54.7% of all patients had ?1 prespecified medical events (USA 52.5%; OC 56.5%). Annualized relapse rates decreased in both regions after starting sc IFN ?-1a, but were higher in the USA (0.83 vs. 0.39); median time to first on-treatment relapse was shorter (USA 14.2; OC 27.2 months).

Conclusions Treatment with sc IFN ?-1a was well tolerated and associated with a reduction in relapses in pediatric patients with MS internationally. Patients in the USA had a higher BMI, a higher frequency of DMD use before sc IFN ?-1a, and a higher relapse rate; factors driving these differences remain to be determined.

Authors/Disclosures
Lauren B. Krupp, MD, FAAN (NYU Langone Medical Center) PRESENTER	Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EBIX. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman LaRoche. Dr. krupp has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for MMMK. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Patrick, Dolan, and Kaufman. Dr. krupp has received intellectual property interests from a discovery or technology relating to health care.
Daniela Pohl, MD	No disclosure on file
	No disclosure on file
Angelo Ghezzi, MD	No disclosure on file
	No disclosure on file
Silvia Tenembaum, MD	Dr. Tenembaum has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech-Roche Inc. . Dr. Tenembaum has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech-Roche Inc. . Dr. Tenembaum has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals Inc. .
	No disclosure on file
	No disclosure on file
	No disclosure on file
Lorenz Lehr, PhD	No disclosure on file
Brenda L. Banwell, MD, FAAN (Childrens Hospital of Philadelphia)	Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH.

��ɫ��

��ɫ��